Novo Nordisk Signs a Five-Year Agreement with UVA Center for Diabetes Technology for Type 2 Diabetes

 Novo Nordisk Signs a Five-Year Agreement with UVA Center for Diabetes Technology for Type 2 Diabetes

Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Shots:

  • UVA in collaboration with Novo Nordisk to co-develop virtual patient modeling for T2D patients. The collaboration will utilize UVA’s work and insights on patient simulation and data-driven models within diabetes and will initially have 15 employees with an expectation of increment
  • The focus of the collaboration is developing ‘virtual innovation lab’ for gaining deep insight of T2D patients and enable simulation of the human metabolic system of different type for T2D patients
  • The collaboration will also expand UVA’s data-driven models, analytics, computer simulation and artificial intelligence

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post